Compare SMX & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMX | MDXH |
|---|---|---|
| Founded | N/A | 2003 |
| Country | Ireland | Belgium |
| Employees | 19 | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 21.1M |
| IPO Year | N/A | 2021 |
| Metric | SMX | MDXH |
|---|---|---|
| Price | $15.65 | $0.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 44.7K | ★ 786.3K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $0.40 |
| 52 Week High | $490.00 | $5.33 |
| Indicator | SMX | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 57.50 | 29.77 |
| Support Level | $15.39 | N/A |
| Resistance Level | $17.72 | $3.79 |
| Average True Range (ATR) | 1.89 | 0.05 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 66.38 | 23.35 |
SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.